>
NEW PAPER REVEALS HOW ANONYMOUS AGENTS ERASE YEARS OF VACCINE SAFETY AND...
72 Straight Hours Of Major Outages Doesn't Seem Like A "Coincidence" To Me
Strategy And The Endless Reinvention Of Nothing
Inside the 007 casting, including the mistake that cleared the way for Robert Pattinson...
SpaceX Just Caught Starship on Its FIRST Attempt!
Solid-State Cells Can Make The U.S. Competitive In Batteries Again: CEO
Jetson ONE personal eVTOL pod is about to go full sky patrol
America's INSANE BREAKTHROUGH Could Replace Septic Tanks Forever
Amazing DIY Building Material for Home & Yard - Inexpensive and Easy!
Researchers have discovered a massive deposit of hidden water...
Amazon's Ring Unveils Flying Drone And Robot To Patrol Homes And Businesses
Anthropic Strikes $3.4 Billion Off-Grid Power Agreement to Bypass U.S. Grids, Reports Say
The X-ray room just shrank to the size of a laptop
Gritt and MasTec partner to bring physical AI to solar construction sites

In a letter to the drugmaker, the FDA said the agency approved Beyfortus, an RSV monoclonal antibody, as a defense against RSV lower respiratory tract disease — but that Sanofi has been claiming it protects broadly against RSV disease, which occurs in the lower and upper tracts. Beyfortus has come under scrutiny following reports of at least two infant deaths during clinical trials for the drug.
The U.S. Food and Drug Administration (FDA) is accusing Sanofi of making false or misleading promotional claims about Beyfortus, a preventative treatment for RSV, Fierce Pharma reported.
In a letter to the drugmaker, the FDA said it approved Beyfortus specifically as a defense against respiratory syncytial virus (RSV) lower respiratory tract disease — but that Sanofi has been claiming it protects broadly against RSV disease, which occurs in the lower and upper tracts.
The company has sent providers emails urging them to give the shot to "help prevent RSV disease in infants."
The promotional materials included other similar statements, including, "Beyfortus is a monoclonal antibody that helps prevent RSV disease starting from Day 1 after injection," and "Your efforts in immunizing infants against RSV disease can impact the population health burden in your community."